OBJECTIVE: The aim of this retrospectively study was to evaluate the clinical efficacy of Aidi injection (ADI) combined with FOLFOX4 chemothreapy regimen in the treatment of advanced colorectal carcinoma. PATIENTS AND METHODS: One hundred and twenty one patients with pathology confirmed advanced colorectal carcinoma were retrospectively analyzed in the department of colorectal surgery in Union Medical Center, Tianjin (UMC). Of the included 121 cases, 58 subjects received the treatment of ADI combined with FOLFOX4 chemotherapy (experiment group) and the other 63 cases received the FOLFOX4 chemotherapy alone (control group). After two cycles chemotherapy treatment, the short-term clinical efficacy such as complete response (CR), partial response (PR) and objective response rate (ORR) were compared between the two groups. The quality of life improvement and chemotherapy related toxicity were also recorded and analyzed. RESULTS: The response rate including CR, PR and ORR were not statistical different between the experiment group and control group (P > 0.05); The KPS score was significant decrease in the control group compared to that in experiment group (P < 0.05); The risk of developing grade-II nausea vomiting and diarrhea was much lower in experiment than that in control group (Pall < 0.05). CONCLUSION: ADI combined with FOLFOX4 chemotherapy can improve the quality of life and decrease some of the toxicity related to chemotherapy in patients with advanced colorectal cancer.
OBJECTIVE: The aim of this retrospectively study was to evaluate the clinical efficacy of Aidi injection (ADI) combined with FOLFOX4 chemothreapy regimen in the treatment of advanced colorectal carcinoma. PATIENTS AND METHODS: One hundred and twenty one patients with pathology confirmed advanced colorectal carcinoma were retrospectively analyzed in the department of colorectal surgery in Union Medical Center, Tianjin (UMC). Of the included 121 cases, 58 subjects received the treatment of ADI combined with FOLFOX4 chemotherapy (experiment group) and the other 63 cases received the FOLFOX4 chemotherapy alone (control group). After two cycles chemotherapy treatment, the short-term clinical efficacy such as complete response (CR), partial response (PR) and objective response rate (ORR) were compared between the two groups. The quality of life improvement and chemotherapy related toxicity were also recorded and analyzed. RESULTS: The response rate including CR, PR and ORR were not statistical different between the experiment group and control group (P > 0.05); The KPS score was significant decrease in the control group compared to that in experiment group (P < 0.05); The risk of developing grade-II nausea vomiting and diarrhea was much lower in experiment than that in control group (Pall < 0.05). CONCLUSION: ADI combined with FOLFOX4 chemotherapy can improve the quality of life and decrease some of the toxicity related to chemotherapy in patients with advanced colorectal cancer.